<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21926285</article-id><article-id pub-id-type="pmc">3198286</article-id><article-id pub-id-type="publisher-id">0969</article-id><article-id pub-id-type="doi">10.2337/dc11-0969</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Pathophysiology/Complications</subject></subj-group></subj-group></article-categories><title-group><article-title>Adhesion Molecules, Altered Vasoreactivity, and Brain Atrophy in Type 2 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Novak</surname><given-names>Vera</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Peng</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Manor</surname><given-names>Brad</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sejdi&#x00107;</surname><given-names>Ervin</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alsop</surname><given-names>David</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abduljalil</surname><given-names>Amir</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roberson</surname><given-names>Paula K.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Munshi</surname><given-names>Medha</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Novak</surname><given-names>Peter</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><aff id="aff1"><sup>1</sup>Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, Massachusetts</aff><aff id="aff2"><sup>2</sup>Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts</aff><aff id="aff3"><sup>3</sup>Department of Radiology, Ohio State University, Columbus, Ohio</aff><aff id="aff4"><sup>4</sup>Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas</aff><aff id="aff5"><sup>5</sup>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Vera Novak, <email>vnovak@bidmc.harvard.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>15</day><month>10</month><year>2011</year></pub-date><volume>34</volume><issue>11</issue><fpage>2438</fpage><lpage>2441</lpage><history><date date-type="received"><day>24</day><month>5</month><year>2011</year></date><date date-type="accepted"><day>17</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; 2011 by the American Diabetes Association.</copyright-statement><copyright-year>2011</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="2438.pdf"/><abstract><sec id="s1"><title>OBJECTIVE</title><p>To investigate the effects of inflammation on perfusion regulation and brain volumes in type 2 diabetes.</p></sec><sec id="s2"><title>RESEARCH DESIGN AND METHODS</title><p>A total of 147 subjects (71 diabetic and 76 nondiabetic, aged 65.2 &#x000b1; 8 years) were studied using 3T anatomical and continuous arterial spin labeling magnetic resonance imaging. Analysis focused on the relationship between serum soluble vascular and intercellular adhesion molecules (sVCAM and sICAM, respectively, both markers of endothelial integrity), regional vasoreactivity, and tissue volumes.</p></sec><sec id="s3"><title>RESULTS</title><p>Diabetic subjects had greater vasoconstriction reactivity, more atrophy, depression, and slower walking. Adhesion molecules were specifically related to gray matter atrophy (<italic>P</italic> = 0.04) and altered vasoreactivity (<italic>P</italic> = 0.03) in the diabetic and control groups. Regionally, sVCAM and sICAM were linked to exaggerated vasoconstriction, blunted vasodilatation, and increased cortical atrophy in the frontal, temporal, and parietal lobes (<italic>P</italic> = 0.04&#x02013;0.003). sICAM correlated with worse functionality.</p></sec><sec id="s4"><title>CONCLUSIONS</title><p>Diabetes is associated with cortical atrophy, vasoconstriction, and worse performance. Adhesion molecules, as markers of vascular health, have been indicated to contribute to altered vasoregulation and atrophy.</p></sec></abstract></article-meta></front><body><p>Diabetes is associated with microvascular disease, white matter hyperintensities (WMHs), cerebral atrophy (<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>), and functional decline (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>). Hyperglycemia and proatherogenic factors (<xref ref-type="bibr" rid="B5">5</xref>) are main causes of endothelial dysfunction (<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>) and neuronal cell damage (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>). We hypothesized that type 2 diabetes is associated with a chronic inflammation that alters cortical vasoregulation and contributes to regional atrophy. We investigated the relationship between adhesion molecules, as markers of vascular integrity, and regional vasoreactivity, WMHs, and brain tissue volumes in older diabetic and nondiabetic adults.</p><sec id="s5"><title>RESEARCH DESIGN AND METHODS</title><p>We prospectively recruited 147 subjects aged 65.2 &#x000b1; 0.7 years (mean &#x000b1; SE). Of these, 71 had type 2 diabetes (40 males, diabetes duration 10.5 &#x000b1; 1.0 years, 15 treated with insulin, 31 hypertensive, 47 hypercholesterolemic) and 76 were age- and sex-matched nondiabetic control subjects (33 males, 19 hypertensive, 29 hypercholesterolemic). Exclusion criteria were type 1 diabetes; recent history of stroke or myocardial infarction; dementia; significant cardiac, renal, neurologic, and kidney disorders; claustrophobia; and magnetic resonance imaging (MRI)-incompatible implants.</p><sec id="s6"><title>Protocol</title><p>Participants signed informed consent and were admitted to the Clinical Research Center at the Beth Israel Deaconess Medical Center. Antihypertensive medications were withdrawn and fasting serum samples were collected.</p><p>Markers of vascular integrity and inflammation were measured by the quantitative sandwich enzyme immunoassay technique (R&#x00026;D Systems, Minneapolis, MN) and a high sensitivity C-reactive protein (hs-CRP) assay (Immulite-1000; Diagnostic Product, Los Angeles, CA). Functionality was assessed by the Mini Mental State Exam, the Behavioural Assessment of Dysexecutive Syndrome (<xref ref-type="bibr" rid="B10">10</xref>), the Geriatric Depression Scale, and normal walking for 12 min.</p></sec><sec id="s7"><title>MRI</title><p>Anatomical and perfusion images were acquired on a 3T GE HDx MRI scanner using three-dimensional magnetization prepared rapid gradient echo, fluid attenuated inversion recovery, and three-dimensional continuous arterial spin labeling sequences (<xref ref-type="bibr" rid="B11">11</xref>). Regional cerebral vasoreactivity to CO<sub>2</sub> challenges (CO<sub>2</sub>VR) was measured as blood flow response to hypercapnia (CO<sub>2</sub> rebreathing with 95% air and 5% CO<sub>2</sub>) and hyperventilation (<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>). CO<sub>2</sub>VR was calculated as the slope of the regression between perfusion and CO<sub>2</sub> during normocapnia, hypercapnia, and hypocapnia. Flow augmentation during hypercapnia (i.e., vasodilation response, CO<sub>2</sub>VR-VD) and flow reduction during hyperventilation (i.e., vasoconstriction response, CO<sub>2</sub>VR-VC) were quantified. Magnetization prepared rapid gradient echo and fluid attenuated inversion recovery images were coregistered to a standard template and segmented to calculate regional brain tissue and WMH volumes normalized for intracranial volume (SPM7, University College London, U.K.) (<xref ref-type="bibr" rid="B14">14</xref>) (IDL, Research Systems, Boulder, CO; MATLAB, MathWorks, Natick, MA) (<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>). Perfusion and vasoreactivity maps were coregistered with anatomical images.</p></sec><sec id="s8"><title>Statistical analysis</title><p>We used least square models to assess the relationships between adhesion molecules and regional vasoreactivity, gray matter (GM), white matter, cerebrospinal fluid (CSF), and WMHs. Variables with significant correlations (<italic>r</italic><sup>2</sup> &#x0003e;0.1, <italic>P</italic> &#x0003c; 0.05) were included in the models. Overall model fit (<italic>r</italic><sup>2</sup>) and <italic>P</italic> values were calculated separately for each region to minimize repeated measures effects. Models were adjusted for age, sex, and group or glucose. Perfusion models were also adjusted for CO<sub>2</sub> and hematocrit. MANCOVA with Sidak adjustment was used for comparisons across regions and between groups. Demographics and laboratory values were compared by ANOVA and Wilcoxon tests.</p></sec></sec><sec id="s9"><title>RESULTS</title><sec id="s10"><title>Characteristics of diabetic and control groups</title><p>Compared with control subjects, diabetic subjects had elevated fasting glycemia (124.4 &#x000b1; 7.4 vs. 79.3 &#x000b1; 1.6 mg/dL, <italic>P</italic> &#x0003c; 0.0001), HbA<sub>1c</sub> (7.1 &#x000b1; 0.1 vs. 5.4 &#x000b1; 0.1%, <italic>P</italic> &#x0003c; 0.0001), BMI (28.4 &#x000b1; 0.6 vs. 25.3 &#x000b1; 0.6 kg/m<sup>2</sup>, <italic>P</italic> &#x0003c; 0.0001), and tumor necrosis factor-&#x003b1; (1.8 &#x000b1; 0.1 vs. 1.5 &#x000b1; 0.1 pg/mL, <italic>P</italic> = 0.0004). Soluble intercellular adhesion molecule (sICAM; 246.2 &#x000b1; 13.9 vs. 226.5 &#x000b1; 5.8 ng/mL), soluble vascular adhesion molecule (sVCAM; 758.6 &#x000b1; 28.4 vs. 729.9 &#x000b1; 20.7 ng/mL), endothelin-1, interleukin-6, and CRP were not different. Diabetic subjects were more depressed (6.0 &#x000b1; 0.8 vs. 2.8 &#x000b1; 0.9, <italic>P</italic> = 0.003) and walked slower (1.06 &#x000b1; 02 vs. 1.12 &#x000b1; 0.02 m/s, <italic>P</italic> = 0.02) than control subjects.</p><p>Diabetic subjects had lower GM volumes (parietal and occipital lobes and cerebellum, <italic>P</italic> &#x0003c; 0.02) (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>) and greater WMH volume globally (<italic>P</italic> = 0.0004) and in the temporal, parietal, and occipital lobes (<italic>P</italic> &#x0003c; 0.01) (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). Baseline perfusion and CO<sub>2</sub>VR-VD were similar (<xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic></xref>), yet the diabetic group had exaggerated CO<sub>2</sub>VR-VC in the frontal, parietal, and occipital regions (<italic>P</italic> &#x0003c; 0.01) (<xref ref-type="fig" rid="F1">Fig. 1<italic>D</italic></xref>).</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Relationships between adhesion molecules, regional brain volumes, and vasoreactivity: regional GM (<italic>A</italic>), WMHs (<italic>B</italic>), CO<sub>2</sub>VR-VD (<italic>C</italic>), and CO<sub>2</sub>VR-VC (<italic>D</italic>) in the diabetic (black bars) and control groups (white bars). The diabetic group as compared with the control group had lower regional GM volumes, greater WMH load, and exaggerated vasoconstriction reactivity. sVCAM was associated with lower GM volume in the temporal and parietal lobes (<italic>A</italic>) and decreased vasodilatation reactivity (<italic>C</italic>). sICAM was associated with lower GM volume in the frontal, temporal, and parietal lobes (<italic>A</italic>); blunted vasodilatation in the parietal and occipital lobes (<italic>C</italic>); and exaggerated vasoconstriction in the frontal, temporal, parietal, and occipital lobes (<italic>D</italic>) in the diabetic and control groups. WMHs were not related to adhesion molecules. sICAM: &#x02020;<italic>P</italic> &#x0003c; 0.05, &#x02020;&#x02020;<italic>P</italic> &#x0003c; 0.01, &#x02020;&#x02020;&#x02020;<italic>P</italic> = 0.003. sVCAM: &#x02021;<italic>P</italic> &#x0003c; 0.05. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.0001 between group comparisons mean &#x000b1; SE.</p></caption><graphic xlink:href="2438fig1"/></fig><sec id="s11"><title>Adhesion molecules, brain tissue volumes, and vasoreactivity.</title><p>Adhesion molecules were associated with decreased GM volume, exaggerated CO<sub>2</sub>VR-VC, and blunted CO<sub>2</sub>VR-VD in both groups (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic>&#x02013;<italic>D</italic></xref>). sVCAM was linked to lower GM volumes globally (<italic>r</italic><sup>2</sup> = 0.24, <italic>P</italic> = 0.04) and regionally (temporal and parietal, <italic>r</italic><sup>2</sup> = 0.13&#x02013;0.23, <italic>P</italic> = 0.02&#x02013;0.006), greater CSF volumes globally (<italic>r</italic><sup>2</sup> = 0.12, <italic>P</italic> = 0.05) and regionally (temporal and occipital, <italic>r</italic><sup>2</sup> = 0.07&#x02013;0.12, <italic>P</italic> = 0.03&#x02013;0.007), and blunted CO<sub>2</sub>VR-VD (parietal and occipital, <italic>r</italic><sup>2</sup> = 0.12&#x02013;16, <italic>P</italic> = 0.03). Higher sICAM and glucose levels were related to GM atrophy (frontal, temporal, and parietal, <italic>r</italic><sup>2</sup> = 0.14&#x02013;29, <italic>P</italic> = 0.02&#x02013;0.003) and blunted global CO<sub>2</sub>VR-VD (<italic>r</italic><sup>2</sup> = 0.09, <italic>P</italic> = 0.03) and exaggerated CO<sub>2</sub>VR-VC (frontal, temporal, and parietal, <italic>r</italic><sup>2</sup> = 0.12&#x02013;16, <italic>P</italic> = 0.03&#x02013;0.01). sICAM was linked to slower walking (<italic>r</italic><sup>2</sup> = 0.12, <italic>P</italic> = 0.01) and worse behavioral measures (<italic>r</italic><sup>2</sup> = 0.16, <italic>P</italic> = 0.03).</p><p>Within the diabetic group, the relationships between adhesion molecules and brain measures were stronger; sVCAM was associated with GM atrophy (temporal <italic>r</italic><sup>2</sup> = 0.13, <italic>P</italic> = 0.05; parietal <italic>r</italic><sup>2</sup> = 0.4, <italic>P</italic> = 0.02), and sICAM was associated with altered vasodilatation (global <italic>r</italic><sup>2</sup> = 0.32, <italic>P</italic> = 0.02; parietal <italic>r</italic><sup>2</sup> = 0.32, <italic>P</italic> = 0.02). sICAM (<italic>r</italic><sup>2</sup> = 0.24, <italic>P</italic> = 0.0003) and sVCAM (<italic>r</italic><sup>2</sup> = 0.24, <italic>P</italic> = 0.0003) correlated with glycemia but not with HbA<sub>1c</sub>, medications, diabetes duration, or hypertension. In control subjects, sVCAM correlated with greater CSF volume (<italic>r</italic><sup>2</sup> = 0.24, <italic>P</italic> = 0.03). sICAM was related to smaller CSF volume (<italic>r</italic><sup>2</sup> = 0.26, <italic>P</italic> = 0.0007) and greater GM volume (frontal, temporal, and parietal, <italic>r</italic><sup>2</sup> = 0.24&#x02013;43, <italic>P</italic> = 0.01&#x02013;0.003).</p><p>Tumor necrosis factor-&#x003b1;, interleukin-6, endothelin-1, and CRP were not related to brain volumes or vasoreactivity measures. WMHs were not associated with adhesion molecules, inflammation markers, or regional vasoreactivity.</p></sec></sec></sec><sec id="s12"><title>CONCLUSIONS</title><p>Markers of endothelial integrity (sVCAM and sICAM) were specifically associated with altered cortical vasoreactivity and GM atrophy in multiple brain regions in both diabetic and nondiabetic participants. These relationships were independent of WMHs and were not observed for other inflammatory markers. The diabetic group exhibited exaggerated vasoconstriction, more atrophy, lower functionality, and more depression. sVCAM was associated with atrophy affecting temporal and parietal cortices. sICAM and glucose levels were related to exaggerated vasoconstriction and regional cortical atrophy. Adhesion molecules were linked to slower walking and executive and behavioral dysfunction, which are hallmarks of behavioral decline in older adults.</p><p>The relationship between adhesion molecules and vasoreactivity to CO<sub>2</sub> challenges suggests a nitric oxide&#x02013;dependent endothelial dysfunction (<xref ref-type="bibr" rid="B15">15</xref>). Observations of microglial activation and sVCAM expression in the cortex and subcortical areas support this notion and indicate that insulin resistance and obesity may facilitate an inflammatory process in the brain (<xref ref-type="bibr" rid="B9">9</xref>). A combination of altered vasoregulation and hyperglycemia may enhance neurotoxicity of chronic hyperglycemia in the aging diabetic brain.</p></sec></body><back><ack><title>Acknowledgments</title><p>V.N. has received grants from the National Institutes of Health (NIH)&#x02013;National Institute on Aging (NIA) (1R01-AG-0287601-A2), the NIH&#x02013;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5R21-DK-084463-02), and the American Diabetes Association (ADA) (1-03-CR-23 and 1-06-CR-25) related to this study and is also funded by NIH grants for projects unrelated to this study (NIH-NIA 4R37-AG-253705, 1R43-AT-006088-01, R21-AT-005501, and 4P30-AG-02871702). P.Z. has received grants from the NIH&#x02013;NIA (1R01-AG-0287601-A2), the NIH&#x02013;NIDDK, and the ADA (1-06-CR-25). B.M. has received grants from the NIH&#x02013;NIA (1R01-AG-0287601-A2) and NIH (5R21-DK-084463-02) related to this study as well as NIH grants for projects unrelated to this work (R43-AT-06088-01 and R37-AG-025037). E.S. has received grants from the NIH&#x02013;NIA (1R01-AG-0287601-A2) and the NIH&#x02013;NIDDK (5R21-DK-084463-02). D.A. has received grants from the NIH&#x02013;NIA (1R01-AG-0287601-A2) and from the ADA (1-06-CR-25). A.A. has received research support from the Ohio Department of Development. P.K.R. has received grants from the NIH&#x02013;NIA (1R01-AG-0287601-A2) and the NIH&#x02013;NIDDK (5R21-DK-084463-02). M.M. has received grants from the NIH (1R01-AG-0287601-A2) and the NIH&#x02013;NIA (1R01-AG-0287601-A2). P.N. has received research support from the NIH (1R01-AG-0287601-A2 and 1R43-NS-064640-01A2), the NIH&#x02013;NIA (1R01-AG-0287601-A2), the NIH&#x02013;NIDDK (5R21-DK-084463-02), Teva Pharmaceutical Industries, Chelsea Therapeutics, the Langer Family Charitable Foundation, Chirag Foundation Investment Trust, and Baker MSA (Multiple System Atrophy) Research Fund. This study was supported as well by grants from the Harvard Clinical and Translational Science Center (UL1-RR-025758) and the National Center for Research Resources (M01-RR-01032). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or NIH. No other potential conflicts of interest relevant to this article were reported.</p><p>V.N. designed the study and protocol and oversaw all aspects of the study conduct, experiments, and manuscript preparation. P.Z. contributed to study conduct, performed MRI image analysis and statistical analysis, and contributed to manuscript preparation. B.M. contributed to study conduct and to manuscript preparation. E.S. contributed to statistical analysis and manuscript preparation. D.A. oversaw MRI protocols and contributed to MRI analysis. A.A. contributed to MRI analysis. P.K.R. contributed to study design, oversaw statistical analysis, and contributed to manuscript preparation. M.M. contributed to study design and clinical aspects of the study. P.N. contributed to study design, oversaw clinical aspects of the study, and contributed to manuscript preparation.</p><p>Parts of this study were presented in abstract form at the 16th Annual Meeting of the Organization for Human Brain Mapping, Barcelona, Spain, 6&#x02013;10 June 2010.</p><p>The authors acknowledge contributions of Clinical Research Center nursing and MRI staff.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Elderen</surname><given-names>SG</given-names></name><name><surname>de Roos</surname><given-names>A</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><etal/></person-group> <article-title>Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up</article-title>. <source>Neurology</source> <year>2010</year>;<volume>75</volume>:<fpage>997</fpage>&#x02013;<lpage>1002</lpage><pub-id pub-id-type="pmid">20837967</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bresser</surname><given-names>J</given-names></name><name><surname>Tiehuis</surname><given-names>AM</given-names></name><name><surname>van den Berg</surname><given-names>E</given-names></name><etal/></person-group>; <collab>Utrecht Diabetic Encephalopathy Study Group</collab> <article-title>Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source> <year>2010</year>;<volume>33</volume>:<fpage>1309</fpage>&#x02013;<lpage>1314</lpage><pub-id pub-id-type="pmid">20299484</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>WL</given-names></name><name><surname>Qiu</surname><given-names>CX</given-names></name><name><surname>Wahlin</surname><given-names>A</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name></person-group> <article-title>Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study</article-title>. <source>Neurology</source> <year>2004</year>;<volume>63</volume>:<fpage>1181</fpage>&#x02013;<lpage>1186</lpage><pub-id pub-id-type="pmid">15477535</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reijmer</surname><given-names>YD</given-names></name><name><surname>van den Berg</surname><given-names>E</given-names></name><name><surname>de Bresser</surname><given-names>J</given-names></name><etal/></person-group>; <collab>Utrecht Diabetic Encephalopathy Study Group</collab> <article-title>Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors</article-title>. <source>Diabetes Metab Res Rev</source> <year>2011</year>;<volume>27</volume>:<fpage>195</fpage>&#x02013;<lpage>202</lpage><pub-id pub-id-type="pmid">21294241</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Montagnani</surname><given-names>M</given-names></name><name><surname>Koh</surname><given-names>KK</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name></person-group> <article-title>Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms</article-title>. <source>Circulation</source> <year>2006</year>;<volume>113</volume>:<fpage>1888</fpage>&#x02013;<lpage>1904</lpage><pub-id pub-id-type="pmid">16618833</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;kimattila</surname><given-names>S</given-names></name><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name></person-group> <article-title>Endothelial dysfunction in human diabetes</article-title>. <source>Curr Diab Rep</source> <year>2002</year>;<volume>2</volume>:<fpage>26</fpage>&#x02013;<lpage>36</lpage><pub-id pub-id-type="pmid">12643120</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starr</surname><given-names>JM</given-names></name><name><surname>Wardlaw</surname><given-names>J</given-names></name><name><surname>Ferguson</surname><given-names>K</given-names></name><name><surname>MacLullich</surname><given-names>A</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Marshall</surname><given-names>I</given-names></name></person-group> <article-title>Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2003</year>;<volume>74</volume>:<fpage>70</fpage>&#x02013;<lpage>76</lpage><pub-id pub-id-type="pmid">12486269</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group> <article-title>The pathobiology of diabetic complications: a unifying mechanism</article-title>. <source>Diabetes</source> <year>2005</year>;<volume>54</volume>:<fpage>1615</fpage>&#x02013;<lpage>1625</lpage><pub-id pub-id-type="pmid">15919781</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>C</given-names></name><name><surname>Boutin</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>MS</given-names></name><etal/></person-group> <article-title>Brain inflammation is induced by co-morbidities and risk factors for stroke</article-title>. <source>Brain Behav Immun</source> <year>2011</year>;<volume>25</volume>:<fpage>1113</fpage>&#x02013;<lpage>1122</lpage><pub-id pub-id-type="pmid">21356305</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>P</given-names></name><name><surname>Alderman</surname><given-names>N</given-names></name><name><surname>Wilson</surname><given-names>B</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Emslie</surname><given-names>H</given-names></name></person-group> <article-title>The Dysexecutive Questionnaire (DEX)</article-title>. In <source>Behavioral Assessment of the Dysexecutive System</source>. <person-group person-group-type="editor"><name><surname>Wilson</surname><given-names>B</given-names></name><name><surname>Alderman</surname><given-names>N</given-names></name><name><surname>Burgess</surname><given-names>P</given-names></name><name><surname>Emslie</surname><given-names>H</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name></person-group>, Eds. <publisher-loc>Bury St. Edmunds, U.K.</publisher-loc>, <publisher-name>Thames Valley Test Company</publisher-name>, <year>1996</year></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsop</surname><given-names>DC</given-names></name><name><surname>Detre</surname><given-names>JA</given-names></name></person-group> <article-title>Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow</article-title>. <source>J Cereb Blood Flow Metab</source> <year>1996</year>;<volume>16</volume>:<fpage>1236</fpage>&#x02013;<lpage>1249</lpage><pub-id pub-id-type="pmid">8898697</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Last</surname><given-names>D</given-names></name><name><surname>Alsop</surname><given-names>DC</given-names></name><name><surname>Abduljalil</surname><given-names>AM</given-names></name><etal/></person-group> <article-title>Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity</article-title>. <source>Diabetes Care</source> <year>2007</year>;<volume>30</volume>:<fpage>1193</fpage>&#x02013;<lpage>1199</lpage><pub-id pub-id-type="pmid">17290035</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Alsop</surname><given-names>D</given-names></name><name><surname>Abduljail</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Altered vasoreactivity and peri-infarct hyperintensities affect multiple territories in stroke</article-title>. <source>Neurology</source> <year>2009</year>;<volume>72</volume>:<fpage>643</fpage>&#x02013;<lpage>649</lpage><pub-id pub-id-type="pmid">19221298</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Agostino</surname><given-names>E</given-names></name><name><surname>Maes</surname><given-names>F</given-names></name><name><surname>Vandermeulen</surname><given-names>D</given-names></name><name><surname>Suetens</surname><given-names>P</given-names></name></person-group> <article-title>Atlas-to-image non-rigid registration by minimization of conditional entropy</article-title>. <source>Inf Process Med Imaging</source> <year>2007</year>;<volume>20</volume>:<fpage>320</fpage>&#x02013;<lpage>332</lpage><pub-id pub-id-type="pmid">17633710</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kevil</surname><given-names>CG</given-names></name><name><surname>Orr</surname><given-names>AW</given-names></name><name><surname>Langston</surname><given-names>W</given-names></name><etal/></person-group> <article-title>Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway</article-title>. <source>J Biol Chem</source> <year>2004</year>;<volume>279</volume>:<fpage>19230</fpage>&#x02013;<lpage>19238</lpage><pub-id pub-id-type="pmid">14985356</pub-id></mixed-citation></ref></ref-list></back></article>